Spero Therapeutics

(NASDAQ) SPRO

Current Price$2.73

Market Cap$163.28M

Since IPO (2017)-75%

5 Year-82%

1 Year+10%

1 Month+7%

Spero Therapeutics Financials at a Glance

Market Cap

$163.28M

Revenue (TTM)

$54.77M

Net Income (TTM)

$15.24M

EPS (TTM)

$0.24

P/E Ratio

11.57

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$2.73

Volume

649,202.165

Open

$2.84

Price

$2.73

Volume

649,202.165

Open

$2.84

Previous Close

$2.74

Daily Range

$2.73 - $2.87

52-Week Range

$1.80 - $3.22

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$2.73

Volume

649,202.165

Open

$2.84

Previous Close

$2.74

Daily Range

$2.73 - $2.87

52-Week Range

$1.80 - $3.22

Estimated Earnings Date

Aug 11, 2026

SPRO News

Why Spero Therapeutics Stock Is Up 15% Today

James BrumleyJul 1, 2021

Why Spero Therapeutics Shares Are Sliding Today

Keith SpeightsSep 11, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Spero Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Esther Rajavelu, MBA

Website

www.sperotherapeutics.com

Headquarters

Cambridge, MA 02139, US

SPRO Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

25%

Net Income Margin

28%

Return on Equity

35%

Return on Capital

25%

Return on Assets

26%

Earnings Yield

8.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$163.28M

Shares Outstanding

57.90M

Volume

649.20K

Avg. Volume

540.74K

Financials (TTM)

Gross Profit

$59.62M

Operating Income

-$24.00K

EBITDA

-$24.00K

Operating Cash Flow

-$12.62M

Capital Expenditure

$0.00

Free Cash Flow

-$12.62M

Cash & ST Invst.

$40.27M

Total Debt

$2.90M

Spero Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$258.00K

-95.6%

Gross Profit

$258.00K

+103.3%

Gross Margin

100.00%

N/A

Market Cap

$163.28M

N/A

Market Cap/Employee

$5.10M

N/A

Employees

N/A

Net Income

-$7.20M

+48.1%

EBITDA

-$7.54M

+48.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$53.66M

+19.4%

Accounts Receivable

$44.00K

-99.8%

Inventory

$0.00

N/A

Long Term Debt

$507.00K

-76.6%

Short Term Debt

$1.97M

+9.6%

Return on Assets

25.81%

N/A

Return on Invested Capital

25.23%

N/A

Free Cash Flow

$15.86M

+496.4%

Operating Cash Flow

$15.86M

+496.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ABOSAcumen Pharmaceuticals, Inc.

ABOSAcumen Pharmaceuticals, Inc.$2.17+0.93%

HURATuHURA Biosciences, Inc.

HURATuHURA Biosciences, Inc.$2.05+4.07%

SEERSeer, Inc.

SEERSeer, Inc.$1.79+0.00%

CRBPCorbus Pharmaceuticals Holdings, Inc.

CRBPCorbus Pharmaceuticals Holdings, Inc.$7.56+0.00%

CGTXCognition Therapeutics, Inc.

CGTXCognition Therapeutics, Inc.$1.21-6.20%

MCRBSeres Therapeutics, Inc.

MCRBSeres Therapeutics, Inc.$6.28-5.28%

INOInovio Pharmaceuticals, Inc.

INOInovio Pharmaceuticals, Inc.$1.09+1.87%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SUNESUNation Energy

SUNESUNation Energy$5.88+4.20%

INHDInno

INHDInno$39.49+36.61%

NOKNokia

NOKNokia$14.59+0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.26-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.27+0.04%

KEELKeel Infrastructure

KEELKeel Infrastructure$5.66+0.10%

NUNu Holdings

NUNu Holdings$11.60-0.03%

Questions About SPRO

What is the current price of Spero Therapeutics?

Spero Therapeutics is trading at $2.74 per share.

What is the 52-week range for Spero Therapeutics?

Over the past 52 weeks, Spero Therapeutics has traded between $1.80 and $3.22.

How much debt does Spero Therapeutics have?

As of the most recent reporting period, Spero Therapeutics reported total debt of $2.47M.

How much cash does Spero Therapeutics have on hand?

Spero Therapeutics reported $56.13M in cash and cash equivalents in its most recent financial results.

What is Spero Therapeutics’s dividend yield?

Spero Therapeutics does not currently have a dividend yield.

Spero Therapeutics

Spero Therapeutics Financials at a Glance

SPRO News

Why Spero Therapeutics Stock Is Up 15% Today

Why Spero Therapeutics Shares Are Sliding Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Spero Therapeutics

SPRO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Spero Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SPRO

What is the current price of Spero Therapeutics?

What is the 52-week range for Spero Therapeutics?

How much debt does Spero Therapeutics have?

How much cash does Spero Therapeutics have on hand?

What is Spero Therapeutics’s dividend yield?

Premium Investing Services